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1.1 Introduction 
 
Topical delivery system has been introduced to prevent or treat a wide variety of 
diseases, especially diseases related to skin. It is also widely used to deliver 
cosmeceutical active ingredients into skin in order to maintain, improve and nourish the 
physical outlook of human being. Topical products are mostly intended for the localized 
effects at the site of their application by virtue of drug penetration into the underlying 
layers of skin or mucous membranes (Mehta, 2000). Drugs and active ingredients could 
be deliver through a variety of topical formulations including creams, lotions, ointments, 
gels, solutions, suspensions, pastes, sprays and transdermal patches. 
There are number of advantages for drug administration via topical route as 
compared with other administrations. One of the main reasons is to avoid the first pass 
metabolism and gastrointestinal disturbances (Gaur et al., 2013). For example, 
metformin, the first-line oral anti-diabetic drug, has been reported for causing 
abdominal discomfort, nausea and diarrhoea during the treatment (Nyenwe et al., 2011). 
Therefore, topical or transdermal delivery of metformin is one of the possible 
administration route that could minimize its side effect.  
Although oral administration is generally the simplest, most convenient and 
economical route, it is nevertheless problematic because of the unpredictable nature of 
gastrointestinal drug absorption (Raffa, 2010). Some drugs have low oral bioavailability 
as they do not practically well absorb by gastrointestinal muscosa. Alternation of any 
physiological environment, for example, as a result of change in diet, lifestyle, age or 
health status, also affect drug absorption and bioavailability (Raffa, 2010). The present 
of nutrients and foodstuffs in the gastrointestinal tract can affect the absorption of a 
drug by binding to it or by altering the physiologic environment such as pH of the 
stomach and intestines. For example, the penicillin V and tetracycline administrated 
orally with food will not be well absorbed (Finkel et al., 1981) due to the interactions 
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between food components and drugs, thus hinder the antimicrobial efficacy of those 
agents (Watson, 1986). 
The intravenous administration delivers the drug directly into the bloodstream 
and gives the fastest effect to the patient. However, this type of administration is 
inconvenient for the patient and practitioner. In the case of diabetic patient for instance, 
daily injection of insulin will cause painful suffering. This will definitely reduce the 
patient compliances especially to the younger patients. At this junction, topical delivery 
offers ease of application and minimizes the risk of infection via intravenous 
administration (Kwatra et al., 2012; Moody, 2010). An alternative to intravenous 
administration, diabetes patient could avoid daily injection by applying anti-diabetic 
transdermal patch which improved the patient compliances and reduced the painfulness 
and risk of infection (Paudel et al., 2010).  
Topical delivery could be another alternative route for those drugs that may 
cause adverse effect at high dosage. Topical application allows the drugs to be delivered 
in a controlled release rate through the skin as compared to direct injection of the drugs 
into the systemic circulation. The controlled release property of topical delivery could 
minimize the adverse effect of certain drugs.  
Topical application of medicines has obvious advantages in the management of 
localized disease. Topical corticosteroids for example can be applied topically at desired 
site and work effectively in managing dermatitis (Maia et al., 2000). Anesthetic drugs 
such as lidocaine and benzocaine will give a local analgesic effect when directly applied 
on ulcers or inflammation site (Sobanko et al., 2012).  
However, there are imminent challenges for certain drugs or active compounds 
to be topically applied through skin. This is because of the barrier property of skin 
limited the absorption of a wide range of substances. Therefore, the understanding of 
the skin structure and its function is especially important. 
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1.2 The Structure and Function of Skin 
 
Skin is the largest organ of the human body with an average surface area of 1.7 
m
2
 and contributes around 10% of the body weight (Edwards & Marks, 1995; Williams, 
2003). This outermost surface of human body is preventing the ingress of harmful 
chemicals and microorganisms whilst regulating heat and water loss from body (Brisson, 
1974). It is also functions as sense organ via various receptors for temperature, pain and 
touch. In addition, it acts as a physical barrier to the environment and providing 
protection against mechanical insults (Wiechers, 1989).  
 Skin comprises three main distinct layers (Figure 1.1), namely epidermis, dermis 
and hypodermis (from outermost to innermost layer) (Lai-Cheong & McGrath, 2013). 
Epidermis is the outermost multiply layered membrane without blood vessels. The 
thickness of epidermis varies from 0.06 mm on the eyelids to around 0.8 mm on the 
soles of the feet and palms of the hand (Arda et al., 2014). Epidermis contains four 
separate layers (Figure 1.1), from the outside to inside, are the stratum corneum, stratum 
granulosum, stratum spinosum and the stratum basale (Geerligs, 2010). These four 
histologically distinct layers are formed by the differing stages of the keratinocyte 
maturation (Williams, 2003).  
The uppermost layer of epidermis, stratum corneum is the final product of 
keratinocyte maturation and made up of the layers of hexagonal-shaped, non-viable 
cornified cells which known as corneocytes (Bensouilah & Buck, 2006). In stratum 
corneum, corneocytes are surrounded by a cell envelope composed of cross-linked 
proteins and embedded in lipid lamellar regions, which are oriented parallel to the 
corneocytes surface, thereby providing the epidermis with a water impermeable barrier 
(Brisson, 1974; Krutmann & Humbert, 2011; Williams, 2003). Generally, the stratum 
corneum comprises 15 to 20 cell layers with an average thickness around 15 µm 
(Brisson, 1974). The stratum corneum layer plays an essential role in maintaining and 
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structuring the lipid barrier which affords protection against external insults and water 
loss through the skin (Zaidi & Lanigan, 2010). The unique resulting structure of stratum 
corneum has a key role provides the physical barrier for topical and transdermal 
delivery of a wide range of substances. 
The stratum granulosum consists of 1 to 5 layers of flattened polygonal 
granulated cells which undergo final cell differentiation, synthesizes the keratin and 
starts to flatten (Arda et al., 2014; Williams, 2003). At this stage of differentiation, the 
degradation of the viable cell components such as the nuclei and organelles is apparent 
and the cytoplasm of the flattened cells becomes increasingly filled with keratohyalin 
masses and filaments (Geerligs, 2010).  
Stratum spinosum is the thicker cell membrane that consists of 2 to 6 rows of 
keratinocytes which change the morphology from columnar to polygonal cells 
(Williams, 2003). It is formed when the keratinocytes reproduced and matured.  
Stratum basale is the basal layer of epidermis which lies adjacent to the dermis 
and mainly comprised of keratinocytes. The presence of melanocytes which synthesise 
the pigment melanin from tyrosine (Kanitakis, 2002) gives the colour of skin and 
provides protection against ultraviolet (UV) radiation (Lai-Cheong & McGrath, 2013) at 
this layer. 
 Dermis is the major component of skin which composed of a dense network of 
elastic tissue and collagen fibres (Lai-Cheong & McGrath, 2013). This elastic network 
is providing support and flexibility of human skin (Wilkes et al., 1973). The thickness 
of dermis is ranging from 1 mm to 4 mm (Smoller & Hiatt, 2009). Blood vessels, nerves, 
lymph vessels and skin appendages such as sweat glands, sebaceous glands and hairs 
are located in the dermis (Figure 1.1). The extensive vasculature supplies blood flow to 
dermis for regulation of body temperature, delivers nutrients and oxygen to tissue and 
also removing the toxins and waste products.  
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 The innermost layer, hypodermis also called subcutaneous fat layer which is 
mainly composed of adipose tissue that spreads all over the body with the exception of 
the eyelids (Barry, 1983). This sheet of fat layer lies between the overlying dermis and 
the underlying body constituents. The thickness of the hypodermis varies with the age, 
gender, nutritional status and physical conditions of the individual. This fatty layer of 
skin principally serves to insulate the body and acts as mechanical cushion against the 
physical shock. It is also a site that provides a readily available supply of high energy 
molecules for human body. 
 
 
Figure 1.1: Illustration of cross-section through human skin adapted from reference 
(Williams, 2003). 
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1.3 Lipid Nanoparticles 
 
Lipid nanoparticles are nano-sized colloidal particles that composed by lipid and 
stabilized by surfactants (Pardeike et al., 2009). They are derived from o/w emulsions 
by replacing the liquid oil with solid lipid (Jenning et al., 2000). Since the starting 
materials are lipids in solid form, lipid nanoparticles present as rigid particles and being 
solid at both room temperature and body temperature.  
Lipid particles have been used in pharmaceutical application for long time and 
the first fat emulsion namely Intralipid was developed by Wretlind et al. and used for 
parenteral nutrition (Vinnars & Hammarqvist, 2004). This early innovation had opened 
a new chapter in the development especially delivery of lipophilic drugs. Some products 
based on this system like Etomidate, Diazumuls and Lipofundin MCT/LCT had 
successfully been marketed (Davis et al., 1987; Graham et al., 1977; Müller & 
Heinemann, 1994). In the early of nineties, the submicron size of lipid particles were 
reported by Speiser et al. as “Lipid nanopellets” (Speiser, 1990). This study has opened 
up new ideas in which emphasizing the nanotechnology in preparation of lipid particles. 
Later, Müller and his co-workers successfully prepared the lipid nanoparticles by using 
the high pressure homogenization technique (Müller et al., 1995) and then patented this 
invention in 1991 (Lucks & Müller, 1991). Gasco and his co-workers also developed 
and filed another patent describing the preparation of SLN via microemulsion technique 
(Gasco, 1993). 
 
 
  
8 
  
1.3.1 Solid Lipid Nanoparticles 
 
Solid lipid nanoparticles (SLN) have initially been studied by Müller et al. as an 
alternative carrier system to emulsion, liposomes, polymeric nanoparticles (Pardeike et 
al., 2009). Unlike emulsion, the SLNs were produced by replacing the liquid oil of the 
emulsion with single or mixture of solid lipids. Therefore, SLN are mostly solid 
particles with a mean particle size between 40 nm to 1000 nm (Lucks & Müller, 1991). 
In the early stage of SLN research, it was initially focused on pharmaceutical 
applications such as oral and parenteral administration (Wissing et al., 2004), and later 
the interest of SLN research gradually shifted to the topical and transdermal applications 
(Guimarães & Ré, 2011).  
SLNs are beneficial in many aspects such as able to minimize the usage of 
organic solvents, possess negligible toxicity, ease of encapsulation for the lipophilic 
substances, provide protection for incorporated actives and able to increase 
bioavailability of lipophilic compounds (Das et al., 2012; Müller et al., 1995). 
Moreover, the solid matrix nature of SLN has the property of sustained release of drugs 
or active ingredients (Mühlen et al., 1998). SLNs are also possible to penetrate thought 
skin by manifesting its particle size (Priano et al., 2007). 
Although this type of carrier has demonstrated several advantages as excipient, it 
does have some limitations especially of low encapsulation capacity and possible 
expulsion of drug from the matrix during storage. Normally, the preparation of lipid 
nanoparticles involved rapid recrystallization process. The lipid nanoparticles produced 
generally considered less ordered crystal structured (Souto et al., 2006), therefore 
mostly are not stable and tend to transform into more ordered crystal during storage 
(Awad et al., 2009). This rearrangement of the crystal structure could reduce the 
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accommodation spaces in the particles that led to the drug or active ingredient exclusion 
(Jenning & Gohla, 2001). 
 
 
1.3.2 Nanostructured Lipid Carriers 
 
Due to some limitations of SLN, development of new generation of lipid 
nanoparticles has led into what so called nanostructured lipid carriers (NLC) (Das et al., 
2012) which as a result of certain amount of liquid lipid or oil were mixed with solid 
lipid in order to improve the encapsulation efficiency and reduce drug expulsion 
(Jenning et al., 2000). The mixing of liquid oil with solid lipid could lead to a massive 
crystal lattice disturbance and therefore creates enough space to accommodate drug 
molecules, thereby improves the encapsulation efficiency of active compounds (Souto 
et al., 2004; Jenning & Gohla, 2001).  
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1.4 Preparation of Lipid Nanoparticles 
 
 Many different techniques for the preparation of lipid nanoparticles (SLN and 
NLC) have been reported in the literatures (Mehnert & Mäder, 2012). Among these 
techniques, the high pressure homogenization, microemulsion technique and melt-
emulsification combine ultrasonication method were the popular approaches that used 
in preparation of lipid nanoparticles (Anton et al., 2008; Pardeike et al., 2009). 
Basically all the SLN and NLC preparation methods involved two step processes, i.e. 
the formation of o/w lipid nanoemulsion and subsequently recrystallization to obtain the 
nanoparticles.  
 
1.4.1 High Pressure Homogenization 
 
 High pressure homogenization technique has extensively been investigated for 
the preparation of SLN and NLC. Lipid nanoparticles can be prepared by either the hot 
or cold high pressure homogenization technique. In the hot homogenization method, 
molten solid lipid for SLN or mix of solid and liquid lipids for NLC with the active 
ingredients was dispersed in a pre-heated surfactant solution. This mixture was 
emulsified by high speed stirring and then passed through a high pressure homogenizer 
adjusted to the same temperature. The obtained lipid nanoemulsions were left to cool 
down in room temperature.  
In cold homogenization method, the molten lipid with active ingredients was 
cooled down to room temperature. After solidification, the lipid was ground to obtain 
lipid granules and then dispersed in a cold surfactant solution. This mixture was passed 
through the high pressure homogenizer at room temperature to yield nano-sized lipid 
particles. 
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High pressure homogenization technique avoids the use of toxic organic solvents 
and less quantities of water content. Moreover, high pressure homogenization is widely 
used in the production of emulsion for parenteral nutrition in the pharmaceutical 
industry. Therefore, this technique is possible to produce SLN and NLC in industry 
scale. However, this technique has high possibility to degrade the chemically labile 
actives due to the critical preparation condition (high temperature and pressure). 
 
1.4.2 Microemulsion Technique 
 
 Microemulsion can be defined as isotropic and thermodynamically stable o/w or 
w/o dispersion stabilized by emulsifier(s) (Mozafari, 2006). Gasco and his co-workers 
have developed the preparation of SLN through microemulsion technique (Gasco, 1993) 
by mixing a molten lipid with surfactant, co-surfactant generally medium chain alcohols 
such as butanol and water. This hot microemulsion is then dispersed in large amount of 
cold water with stirring. The cooling process leads to rapid recrystallization of the 
microemulsion, thus forming the lipid nanoparticles. 
Although this preparation method do not require high mechanical energy used in 
the formation of nanoparticles, however it is not very practical because the use of 
medium chain alcohol may cause toxicity and irritation (Tenjarla, 1999). In addition, the 
total lipid content in lipid nanoparticles was considerably low due to large amount of 
water used in the cooling process (Mehnert & Mäder, 2012). 
  
12 
  
1.4.3 Melt-Emulsification Combined with Ultrasonication Method 
 
In the melt-emulsification combined with ultrasonication method for the 
preparation of lipid nanoparticles was initially developed by Domb et al. (Domb & 
Maniar, 1991). This preparation starts with the dispersion of drug in the molten lipid 
and subsequently mixed with the pre-heated surfactant solution. This mixture was 
homogenized with high speed homogenizer to form emulsion and further sonicated with 
ultrasonicator to form nanoemulsion. Subsequently, the prepared nanoemulsion was 
dispersed in cold water for recrystallization of the lipid nanoparticles.  
Homogenizer and ultrasonicator are mostly readily accessible equipments, thus 
makes this preparation method becomes one of the popular approach in SLN and NLC 
researches. In general, this method presents a good potential for lipid nanoparticle 
preparation because the formulation parameters are directly controllable. Hence, melt-
emulsification combined with ultrasonication method was used in this study to prepare 
the lipid nanoparticles in this study. 
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Figure 1.2: Schematic diagram of melt-emulsification combine with ultrasonication 
method for preparation of lipid nanoparticles. 
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1.5 Materials Used in Formulation of Lipid Nanoparticles 
 
SLN and NLC can be prepared from different types of starting material such as 
triglycerides, phospholipids and waxes (Han et al., 2008; Jenning et al., 2000; 
Kheradmandnia et al., 2010; Tsai et al., 2012). Among them, fatty acid is one of the 
most cost effective raw materials and therefore has widely been used in order to reduce 
the production cost. Hence, fatty acids were used as raw materials in the preparation of 
lipid nanoparticles in order to develop cost effective carrier system. In this present work, 
a series of stearic acid lipid nanoparticles incorporated with different ratio of oleic acid 
were prepared and named stearic-oleic acid nanoparticles (SONs). 
 
1.5.1 Fatty Acids 
 
Fatty acids are the main components in the preparation of SONs. They are a 
class of monocarboxylic acid with a hydrocarbon chain, which is either saturated or 
unsaturated or branched. In this work, fatty acids with single hydrocarbon chain were 
chosen in the preparation of lipid nanoparticles. Generally, fatty acids have the 
hydrocarbon chain with even number of carbon atoms in natural sources. Fatty acids 
present in the form of ester in triglycerides, phospholipids and glycolipids. They are the 
important energy source for our body. Fatty acids are metabolized in our body to obtain 
a large amount of adenosine-5'-triphosphate (ATP) to supply energy for our daily 
activities (Mangold, 1995). 
The chemical and physical properties of fatty acids are varying with their 
occurrences. Saturated fatty acids exist as powder or solid form in room temperature 
whereas unsaturated fatty acids appear in liquid form even both fatty acid molecules 
having same number of carbon atoms. Unsaturated fatty acids with one or more double 
bonds in their hydrocarbon chains and can occur in cis or trans configuration. The 
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natural unsaturated fatty acids obtained in plants have double bond with cis 
configuration whereas the synthetic fatty acids generally occur in trans configuration. 
Fatty acids can be categorized into several groups based on their fatty acid chain 
length (Mangold, 1995):  
 Short-chain fatty acids are fatty acids with hydrocarbon chain of fewer 
than six carbons; 
 Medium-chain fatty acids are fatty acids with aliphatic tails of 6 to 12 
carbons; 
 Long-chain fatty acids are fatty acids with hydrocarbon chain of more than 
12 carbons. 
Essential fatty acids are fatty acids required in human body but cannot be 
generated by ourselves (Simopoulos, 1991). Therefore, essential fatty acids have to be 
consumed from food. The important sources to obtain essential fatty acids are from 
plant oils and fish oils. Examples of essential fatty acids are linoleic acid, linolenic acid, 
arachidonic acid and others. 
Stearic acid and oleic acid were used to produce SONs in this work because they 
are non-toxic, biocompatible with our body, cost effective and easily obtain from plants 
especially palm oil. This also would be an additional value for oil palm products.  
Stearic acid (Figure 1.3) is the saturated carboxylic acid with a hydrocarbon 
chain consists of 18 carbon atoms and has the IUPAC name called octadecanoic acid. 
Its name comes from the Greek word “stéar”, meaning tallow and was first described by 
Chevreul et al. in 1823 (Leray, 2012). Its empirical formula is C18H36O2 with molar 
mass of 284.48 g mol
-1
. It appears as shiny white flakes or powder and very slightly 
soluble in water. Its melting point is at 69-70°C and boiling point at 383°C.  
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Stearic acid occurs as glycerol ester in animal and vegetable fats where it is one 
of the most abundant long chain saturated fatty acid that found in nature. It is the major 
composition of cocoa butter (33.2%) and beef tallow (18.9%) also can be obtained from 
palm oil (4.4%) and palm kernel oil (2.8%) in Malaysia (Denke, 1994). Stearic acid is 
widely used as ingredient in making candles, soaps, plastics, lubricant, cosmetics and 
pharmaceutical products. 
 
 
Figure 1.3: Molecular structure of stearic acid (octadecanoic acid). 
Oleic acid (Figure 1.4) is the monounsaturated fatty acid consists of a single 
hydrocarbon chain with 18 carbon atoms and one cis double bond that located between 
9
th
 and 10
th
 carbon atom. Its molecular formula is C18H34O2 with molar mass of 282.42 
g mol
-1
. It was also discovered by Chevreul et al. in his pioneering studies on pork fat in 
1823 (Stillwell, 2013). Oleic acid presents as colourless oil at room temperature and 
insoluble in water. The melting point of pure oleic acid is at 4°C and boiling point at 
286°C.  
Oleic acid is abundantly found in the form of glycerol ester in vegetable oils and 
also can exist in the form of ethyl ester in animals and man (Leray, 2012). The sources 
of oleic acid for human consumption are olive oil (about 60-70%), nut oils, canola oil, 
sesame oil, cocoa butter, lard, palm oil and soybean oil (Leray, 2012).  
 
Figure 1.4: Molecular structure of oleic acid (cis-9-octadecenoic acid). 
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1.5.2 Surfactants 
 
Surface active agents or surfactants are one of the important components in 
preparation of SONs because they functioned as emulsifier in the emulsification process 
and stabilizer for nanoparticles. Surfactants are amphiphilic molecules that consist of 
non-polar hydrophobic portion, usually a straight or branched hydrocarbon chain 
containing 8 to 18 carbon atoms with or without C=C double bonds, which is attached 
to a polar or ionic functional group (hydrophilic). The polar or ionic head group 
interacts strongly with water molecules, whereas the non-polar hydrocarbon chain 
interacts strongly with organic molecules. Due to this amphiphilic characteristic, 
surfactant has the ability to adsorb at the interface when present at low concentration 
altering the interfacial energies of interfaces (boundary between any immiscible phases). 
The general illustration of surfactants is shown in Figure 1.5.  
 
Figure 1.5: Schematic diagram of a surface active agent. 
 
Surfactants can be classified based on their nature of polar head group namely 
categorised as anionic, cationic, amphoteric and non-ionic (Tadros, 2006). Anionic 
surfactants are the surfactants with the anionic functional group attached with non-polar 
Non-polar hydrocarbon 
chain 
Polar or ionic functional 
group 
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hydrocarbon chain. They are the most widely used surfactants in laundry industry due to 
their low production cost and practically compatible in every type of detergents.  
The most common cationic surfactants are quaternary ammonium compounds 
with alkyl group such as cetyl trimethylammonium bromide (Table 1.1). They were 
widely used in hair conditioner, softener, antistatic agents and bactericides due to their 
positive charges on the polar head group able to absorb at negatively charged surface.  
Amphoteric or zwitterionic surfactants are surfactants containing both cationic 
and anionic functional groups. N-alkyl betaines (Table 1.1) are the common example of 
this class of surfactants. They have isoelectric property where the molecules become 
positive charge in low pH, whereas they behave like anionic surfactants in alkaline 
solution. They were frequently used in personal care products because of low eye 
irritation.  
Non-ionic surfactants are also widely used in food, cosmetic and pharmaceutical 
industries because of its low toxicity, less irritation to eye and mild to skin. They can be 
distinguished to several classes: sorbitan ester ethoxylates, alcohol ethoxylates, 
monoalkaolamide ethoxylates, glycol esters, glucosides, sucrose esters, polymeric 
surfactants and others (Tadros, 2006). 
The non-ionic surfactants that used in preparation of SONs were ethoxylated 
fatty acid esters of sorbitan (Tweens). Tweens type surfactants were commonly used in 
cosmetic and pharmaceutical industries, sometime even in food industry. Tweens are 
ethoxylated derivative of fatty acid ester of sorbitan (Span). The hydroxyl moieties on 
sorbitan esters could react with ethylene oxide to produce Tweens. Generally, they have 
a bulky polar head group which contained twenty units of ethylene oxides. The 
polyethylene moieties of Tweens change the lipophilic property of sorbitan esters to 
hydrophilic and increased the number of HLB of Tweens. In addition, the polyethylene 
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moieties of Tweens make them appear as viscous liquid at room temperature. The bulky 
polar head group of Tweens has relatively high steric effect to stabilize the emulsion 
droplets. Tween type surfactants can further react with fatty acid to form polyethylene 
sorbitan di- or tri-esters, but sorbitan tri-esters are more common to be used in food, 
cosmetic and pharmaceutical industries (Tadros, 2006). Molecular structure of Tween 
60 is shown in Table 1.1. 
 
Table 1.1: Examples of different types of surfactants that commonly used in 
cosmetic and pharmaceutical industries. 
Surfactant 
Type 
Example 
Anionic  
 
Cationic  
 
Zwitterionic 
 
Nonionic  
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1.6 Lipid Nanoparticles as Advanced Topical Delivery System 
 
 Topical application has widely been used as delivery system for cosmetic and 
pharmaceutical application. However, the conventional topical formulation (e.g. 
emulsion) normally associated with low uptake due to the barrier function of the stratum 
corneum and potential absorption to the systemic circulation (Benson, 2000; Jayaraman 
et al., 1996; Jenning et al., 2000) that make it a complex system. Therefore, lipid 
nanoparticles were introduced as advanced topical delivery systems in order to 
minimise these problems (Pardeike et al., 2009).  Lipid nanoparticles have extensively 
been investigated as delivery system especially for cosmetic and pharmaceutical 
applications. A wide range of substances has been incorporated into lipid nanoparticles 
for topical formulation. Example of these active ingredients and drugs are summarised 
in Table 1.2.  
 
Table 1.2: Examples of active ingredients and drugs incorporated into lipid 
nanoparticles for topical application. 
Incorporated Active 
Ingredients and Drugs  
Application Reference 
Ascorbyl palmitate Antioxidant Üner et al., 2005 
Benzocaine Anaesthetic agent Puglia et al., 2011 
Butylmethoxydibenzoyl
methane 
UV filter Scalia et al., 2011 
Clotrimazole Antifungal agent Souto et al., 2004 
Coenzyme Q10 Antioxidant Teeranachaideekul et al., 2007 
Glucocorticoids Dermatitis Maia et al., 2000 
Ketoconazole Antifungal agent Ramasamy et al., 2012 
Lidocaine Anaesthetic agent Pathak & Nagarsenker, 2009 
Retinoic Acid Acne treatment Castro et al., 2007 
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Lipid nanoparticles have been used for dermal application due to many 
advantages features of these carrier systems over conventional formulation such as it 
occurs as rigid particles at both room temperature and body temperature, enhances 
percutaneous absorption and prolongs release of its payload. As discussed at Section 1.2, 
stratum corneum is the physical barrier of skin that limits the percutaneous absorption 
of active substances into the skin. Lipid nanoparticles have been developed as one of the 
approaches to improve skin penetration of active ingredients. Pardeike et al. reported 
that the coenzyme Q10 loaded in NLC has higher skin penetration as compared to liquid 
paraffin and emulsion (Pardeike & Müller, 2007). Moreover, Schwarz et al. in their 
work proved that smaller particles improved the skin penetration by manifesting the 
particle size of coenzyme Q10 loaded NLC to ultra-small size (<100 nm) (Schwarz et 
al., 2013). However, the penetration of active ingredients through skin was also affected 
by the composition of lipid nanoparticles (Schlupp et al., 2011). 
Numerous studies have shown that lipid nanoparticles have the ability for 
prolong release of its payloads (Hu et al., 2005; Puglia et al., 2011; Souto et al., 2004; 
Jenning et al., 2000). This controlled release mechanism prevents a sudden intake of 
high concentration of irritating compounds into skin and also improve therapeutic 
efficacy of certain drugs such as anaesthetic or antimicrobial agents (Kheradmandnia et 
al., 2010; Leng et al., 2012). 
Lipid nanoparticles have high potential to be commercial as the cosmetic and 
pharmaceutical products because it is easily mixed into the conventional formulations 
like gels or creams. Ketoconazole loaded SLN was successfully formulated into 
hydrogel and performed effectively in treatment of candidiasis (Ramasamy et al., 2012). 
Flurbiprofen loaded lipid nanoparticles gels also showed a sustained anti-inflammatory 
activity for longer period of time (Bhaskar et al., 2009). Nanolipid dispersion containing 
clotrimazole has been incorporated into base creams and showed longer release 
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character as compared to commercial creams (Souto & Müller, 2007). Indeed, some 
cosmetic products containing the SLN and NLC have been marketed as listed in Table 
1.3. 
 
Table 1.3: Examples of marketed lipid nanoparticles cosmetic products. 
Product Name Manufacturer Date of Product Launched 
Cutanova Cream Nano 
Repair Q10 
Dr. Rimpler 10/ 2005 
Nanolipid Q 10 CLR 
Chemisches Laboratorium 
Dr. Kurt Richter, (CLR) 
07/ 2006 
NLC Deep Effect Repair 
Cream 
Beate Johnen 12/ 2006 
Regenerationscreme 
Intensive 
Scholl 06/ 2007 
SURMER Crème Contour 
Des Yeux 
NanoRemodelante 
Isabelle Lancray 03/ 2008 
Olivenöl Anti Falten 
Pflegekonzentrat 
Dr. Theiss 02/ 2008 
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1.7 Objectives of Research 
 
1. To prepare and characterize the physicochemical properties of stearic-oleic 
acid nanoparticles. 
2. To investigate encapsulation efficiency of salicylic acid and lidocaine 
loaded stearic-oleic acid nanoparticles. 
3. To study the load release kinetics of stearic-oleic acid nanoparticles in 
cream. 
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2.1 Materials  
 
Stearic acid with 95.0% purity and oleic acid with 99.0% purity were purchased 
from Sigma-Aldrich (St. Louis, USA) and Fluka (Buchs, Switzerland). 
Tween series surfactants with 12 to 18 carbon hydrocarbon chain (Tween 20, 
Tween 40 and Tween 60) were obtained from Lasem Asia (Kuala Lumpur, Malaysia) 
and Sigma-Aldrich (St. Louis, USA). Salicylic acid (99.0%) and methanol (99.9%) 
were purchased from Merck (Darmstadt, Germany). Lidocaine with 98.0% purity and 
phosphate buffer saline (PBS) tablets (pH 7.4) were purchased from Sigma-Aldrich (St. 
Louis, USA). Salcare
®
 SC91 based cream was obtained from BASF (Ludwigshafen, 
Germany). 
All solutions and samples were prepared by using deionized water with a 
resistivity of 18.2 Ω cm-1, from a Barnstead Diamond Nanopure Water Puriﬁcation unit 
coupled with a Barnstead DiamondTM RO unit (Barnstead International, USA). 
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2.2 Preparation of SONs  
 
 SONs were prepared by melt-emulsiofication combined with ultrasonication 
method. The composition of SON without oleic acid that used in the early investigation 
of SONs preparation as listed in Table 2.1.  
Table 2.1: Weight composition of SON preparation. 
Composition Weight (g) 
Stearic acid 0.500 
Tween 60 0.125 
Water 5.000 
 
The lipid phase, stearic acid was melted and dispersed in the pre-heated Tween 
60 solution. This mixture was homogenized by using homogenizer (SilentCrusher M, 
Heidolph Instruments, Germany) at 75°C to form emulsion. It was then further 
sonicated by using ultrasonic liquid processor model XL 2015 (USA). The 
nanoemulsion obtained was then poured into cold water to form nanoparticles.  
Another series of SONs with different ratio of oleic acid were prepared for 
further investigations. In the preparation of SONs without the active ingredients, the 
lipid phases, stearic acid (0 wt% of oleic acid) or mixture of stearic acid and oleic acid 
with 10, 20, 30, 40 and 50 wt% oleic acid content, respectively, were prepared and 
melted at 75°C. The molten lipid phases were mixed with pre-heated surfactant 
solutions. The mixtures were homogenized then further treated by ultrasonicator to form 
nanoemulsions. After that, the nanoemulsions were then poured into 20 mL of cold 
water (about 2°C) to form SON nanoparticles. SON dispersions containing salicylic 
acid or lidocaine were prepared exactly the same manner by only adding salicylic acid 
or lidocaine into the lipid phases above. All SON dispersions were stored at 5°C after 
preparation. 
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2.3 Particle Size and Polydispersity Index of SONs  
 
 The average particle size and polydispersity index of the SONs were measured 
by using ZetaSizer ZS (Malvern Instruments, UK) with a red Helium laser of 
wavelength λo = 633 nm and at a backscattering angle of 7°. The average diameter of the 
particles was calculated by using the Stokes-Einstein equation with the assumptions that 
the particles are spherical and no interaction between them as shown in the following 
equation, 
3
kT
d
D

     (1) 
where d  is diameter of the particles, the k  is the Boltzmann’s constant, T  is the 
absolute temperature of the sample,   is the viscosity of the medium and D  is the 
diffusion coefficient. In a monodisperse suspension, the correlation function of the 
scattered intensity ( ')C t  can be written as mono-exponential decay functions, 
 ( ') 1 exp 2 'cC t A B t         (2) 
where is cA  is the baseline of the correlation function, B  is the intercept of the 
correlation function,   is the relaxation time which equal to 
22Dq , D  is the diffusion 
coefficient, q  is the scattering vector that which equal to 7
4 '
sin
2
n 

 
 
 
, 'n  is the 
refractive index of medium, 
7
  is backscattering angle of measurement and 't  is time 
delay between two intensities measurements. The average hydrodynamic diameter could 
be determined from the diffusion coefficient, D. The particle size distribution could be 
obtained from the equation (2) and the width of the size distribution compared to the 
median value is known as polydispersity index. The smaller value of polydispersity 
which closes to 0 indicated that the particle size of the sample is uniformly distributed.  
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Approximately, 0.5 ml of SON dispersion was diluted to 25 ml with deionized 
water and was equilibrated to room temperature for 10 min. A 1 cm path length clear 
quartz cuvette was used for the particle size measurement. All measurements were 
performed at a constant temperature of 25°C. Mean particle size and polydispersity 
index were obtained from triplicate measurement of each diluted SON solution whereby 
each measurement consisting of 5 runs on the sample.  
SON suspensions prepared were divided into three vials and kept at 5°C, room 
temperature (28°C) and 45°C, respectively, for particles stability investigation. 
Measurements of the mean particle size of SON were performed throughout a period of 
28 days.  
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2.4 Zeta Potential Measurement 
 
Zeta potential is one of the characterizations that useful for the assessment of the 
physical stability of colloidal dispersions. The particle with larger value of zeta potential 
would have the higher degree of repulsion among the similarly charged particles in the 
dispersion. Generally, suspended particles are considered to be stable when absolute 
value of zeta potential is above 30 mV (Müller et al., 2001). Electrophorestic mobility 
of SONs was measured by using ZetaSizer ZS (Malvern Instruments, UK) at 25°C. By 
using parameters obtained and knowing the viscosity and dielectric constant of sample, 
the zeta potential value can be calculated by using Henry equation as shown in the 
following equation. 
2 ( )
3
E
f ka
U


      (3) 
where 
EU  is electrophoretic mobility,   is dielectric constant of medium,   is zeta 
potential, ( )f ka  is Henry’s function,   is viscosity of SON dispersion. Henry’s 
function is related to Debye length ( k ) and reciprocal of Debye length ( 1k  ) provides 
the information of electric double layer thickness for a particle. Hence ka is deduced as 
ratio of the particle radius to the thickness of electric double layer   / 1/a k . 
Smoluchowski approximation is applied for particle present in the polar solvent with 
 F ka  = 1.5 whereas Hückel approximation with  F ka  = 1.0 is used in the 
calculation for a non-polar solvent. SON dispersion was diluted 25 times with deionized 
water and was equilibrated to room temperature for 10 min. This measurement was 
carried out using disposable folded capillary cell. All measurements were performed at 
a constant temperature of 25°C. An average value of zeta potential was obtained from 
triplicate measurement of each diluted SON solution whereby each measurement 
consisting of 12 runs on the sample.  
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2.5 Determination of Critical Micelle Concentration (CMC) of Surfactants  
 
 The effect of the surfactant hydrocarbon chain on the particle size of SONs 
could be explained by comparing the CMC of the surfactants. The CMC of Tween 20, 
Tween 40 and Tween 60 were determined by measuring the surface tension using the 
Du Nuoy ring method. A stock solution of 1 mmol L
-1
 of Tween surfactant was 
prepared by dissolving appropriate amount of Tween surfactant in 100 ml deionized 
water. The stock solution was left to equilibrate at room temperature for overnight prior 
to any measurement. 
A series of 50 ml solution with different concentration of Tween surfactants 
were prepared by diluting the surfactant stock solution with deionized water. The series 
of the surfactant solution prepared were let to equilibrate at room temperature for 
overnight prior to the surface tension measurement.  
The sample solutions were filtered through a 25 mm diameter 0.2 µm pore size 
Minisart
®
NY nylon filter (Germany) prior to measurements. The CMC determinations 
were carried out via tensiometer balance from KRUSS with K 12 tensiometer processor 
via Du Nuoy ring method. The ring was initially cleaned and heated to red-hot with 
Bunsen burner before use. The samples were equilibrated at 30°C for 10 min prior to 
measurements. All measurements were performed at a constant temperature of 30°C 
throughout the experiments. 
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2.6 Transmission Electron Microscopy (TEM) 
 
 The morphological observations of SONs were obtained by using Energy 
Filtered TEM model LIBRA 120 equipped with an Olympus SIS-iTEM (version 5). 
Samples were diluted to around 0.8 wt% with deionized water and equilibrated at room 
temperature for 5 min. A piece of carbon-coated 400 mesh copper grid was held by 
using forceps and a drop of SON dispersion was placed onto the shinning side of the 
carbon-coated 400 mesh copper grid. After 1 min, the excess dispersion droplet was 
then removed by using a piece of filter paper. It was then negatively stained with a drop 
of 2% phosphotungstic acid solution and left for 1 min. The grid was air-dried at room 
temperature for 30 min and then ready to be examined under TEM.    
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2.7 Differential Scanning Calorimetry (DSC) Analysis 
 
 DSC is one of the thermal analyses that usually used to obtained information on 
the physical and energetic properties of sample. DSC analysis has been widely used to 
determine the state and the degree of the crystallinity of lipid nanoparticles (Bunjes & 
Unruh, 2007). It allows the study of the melting and crystallization behavior of 
crystalline state in lipid nanoparticles. The loading capacity was generally associated 
with the degree of crystallinity because the crystalline state in lipid nanoparticles 
determined the accommodation spaces of payload ingredients. The degree of 
crystallinity is defined as the percentage of the crystalline state in the lipid matrix that 
has recrystallized during the cooling process in the preparation of lipid nanoparticles. 
The degree of crystallinity of SONs was determined by calculating the ratio of SON 
enthalpy to stearic acid enthalpy as shown by the following equation:   
100%SON
SA
H
CD
H
 
  
 
    (4) 
where CD is degree of crystallinity of SON, HSON is enthalpy of SON and HSA is the 
enthalpy of pure stearic acid, respectively. Thermal behaviours of SONs were analysed 
by using Tzero
TM
 DSC Q 20 (TA Instruments, USA). Approximately, 1 ml of SON 
dispersions was dried in a desiccator for 24 hours prior to DSC analysis. About 6 mg of 
air-dried SON sample was weighed into 40 µL aluminium sample pan. An empty 
sample pan was used as a reference. The heating run was performed from 35°C to 80°C 
with the heating rate of 5°C min
-1 
by continuously flushing the nitrogen gas at the rate 
of 20 mL min
-1
. The DSC parameters such as melting point, onset temperature, melting 
enthalpy were analysed by using TA Universal Analysis software (TA Instruments, 
USA).   
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2.8 Preparation of Standard Concentration Curve of Salicylic Acid for UV-
Visible Spectrophotometry Measurement 
 
A stock solution of 100 mg L
-1
 of salicylic acid solution was prepared by 
dissolving 10 mg salicylic acid in 50 mL deionized water and then made up to 100 mL 
in a volumetric flask. After that, a series of salicylic acid solution with the concentration 
of 2.5 mg L
-1
, 5 mg L
-1
, 10 mg L
-1
, 20 mg L
-1
 and 40 mg L
-1
 were prepared by diluting 
the salicylic acid stock solution. The prepared salicylic acid solutions were measured 
spectrophotometrically by using Varian UV-visible spectrophotometer model Cary 50 
(Agilent technologies, US) at the wavelength of 297 nm and the standard concentration 
curve of salicylic acid was plotted. 
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Figure 2.1: UV-Vis absorption spectrum and standard concentration curve (small) of 
salicylic acid in deionized water at 25°C. 
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2.9 Preparation of Standard Concentration Curve of Lidocaine for UV-Visible 
Spectrophotometry Measurement 
 
A stock solution of 300 mg L
-1
 of lidocaine solution was prepared by dissolving 
30 mg lidocaine in 50 mL deionized water and then made up to 100 mL in a volumetric 
flask. The lidocaine stock solution was sonicated to ensure the lidocaine crystal was 
totally dissolved in the deionised water. A series of lidocaine solutions with the 
concentration of 10 mg L
-1
, 25 mg L
-1
, 50 mg L
-1
, 100 mg L
-1
, 150 mg L
-1
 and 250 mg 
L
-1
 were diluted from the stock solution with deionized water. The prepared lidocaine 
solutions were measured spectrophotometrically at the wavelength of 263 nm. Then, the 
standard concentration curve of lidocaine was plotted with the data obtained. 
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Figure 2.2: UV-Vis absorption spectrum and standard concentration curve (small) of 
lidocaine in deionized water at 25°C.  
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2.10 Encapsulation Efficiency of SONs  
 
 Encapsulation efficiency of salicylic acid or lidocaine loaded SON was 
determined using centrifugal ultrafiltration method (Figure 2.3). SON dispersion was 
placed into the upper chamber of centrifugal filter tubes with 50000 Da molecular 
weight cut-off (Vivaspin 6, Sartorius Stedim Biotech, Germany) and centrifuged for 30 
min at 8000 rpm. Then, the concentration of free salicylic acid or lidocaine in the 
supernatant was determined spectrophotometrically by using UV-visible 
spectrophotometer with 1 cm path length clear quartz cuvette at a constant temperature 
of 25°C which thermostatically controlled by a Peltier unit and cooled with water 
circulator. The amount of salicylic acid or lidocaine in each sample was determined 
from the standard concentration curves (Figure 2.1 and 2.2). Encapsulation efficiency 
was calculated by the following equation:  
100%T F
T
W W
EE
W
 
  
 
          (4) 
where EE is encapsulation efficiency of SON, WT is the weight of salicylic acid or 
lidocaine added during preparation and WF is the weight of free salicylic acid or 
lidocaine in the supernatant, respectively. 
 
 
Figure 2.3: Schematic diagram of centrifugal ultrafiltration by using Vivaspin. 
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2.11 Sample Preparation for In Vitro Release Evaluation 
 
Eight different samples were prepared for the in vitro release evaluation. The 
first four different samples of salicylic acid solution, salicylic acid cream, salicylic acid 
loaded SON and salicylic acid loaded SON incorporated into cream were denoted as 
Sample A, B, C and D. Sample A was prepared by dissolving salicylic acid in deionised 
water. Sample B was prepared by homogenizing the salicylic acid solution and Salcare
®
 
SC91 base cream obtained from BASF, a raw material that consisted of 8% anionic 
acrylic copolymer dispersed in a 5-8% of medical grade white oil. Sample C is the 
optimized salicylic acid loaded SON dispersion and this SON dispersion was further 
formulated into Salcare
®
 SC91 base cream at the homogenization rate of 5000 rpm for 5 
min to prepare Sample D. 
For the samples which containing lidocaine, these sample were prepared same 
manner as described above with replacing the salicylic acid to lidocaine. Lidocaine 
solution, lidocaine cream, lidocaine loaded SON and lidocaine loaded SON 
incorporated into cream were denoted as Sample E, F, G and H. 
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2.12 Preparation of Standard Concentration Curve of Salicylic Acid for In Vitro 
Release Study 
 
A stock solution of 50 mg L
-1
 of salicylic acid solution was prepared by 
dissolving 5 mg salicylic acid in 50 mL 10 mM PBS (pH 7.4) and then made up to 100 
mL in a volumetric flask. After that, a series of salicylic acid solution with the 
concentration of 1.563 mg L
-1
, 3.125 mg L
-1
, 6.25 mg L
-1
, 12.5 mg L
-1
 and 25 mg L
-1
 
were prepared by diluting the salicylic acid stock solution. The prepared salicylic acid 
solutions were measured spectrophotometrically at the wavelength of 297 nm and the 
standard concentration curve of salicylic acid was plotted. 
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Figure 2.4: UV-Vis absorption spectrum and standard concentration curve (small) of 
salicylic acid in 10 mM PBS solution at 25°C. 
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2.13 Preparation of Standard Concentration Curve of Lidocaine for In Vitro 
Release Study 
 
A stock solution of 50 mg L
-1
 of lidocaine solution was prepared by dissolving 5 
mg lidocaine in 50 mL 10 mM PBS (pH 7.4) and then made up to 100 mL in a 
volumetric flask. After that, a series of lidocaine solution with the concentration of 1.25 
mg L
-1
, 2.5 mg L
-1
, 5 mg L
-1
, 7.5 mg L
-1
, 10 mg L
-1
 and 15 mg L
-1
 were prepared by 
diluting the lidocaine stock solution. The prepared lidocaine solutions were measured 
spectrophotometrically at the wavelength of 263 nm and the standard concentration 
curve of lidocaine was plotted. 
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Figure 2.5: UV-Vis absorption spectrum and standard concentration curve (small) of 
lidocaine in 10 mM PBS solution at 25°C. 
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2.14 In Vitro Release Evaluation 
 
 In vitro Franz diffusion technique was one of the methods for evaluation the in 
vitro release rate of active ingredient and/or drug from the samples. In this study, the 
Automated Franz Diffusion Cell System from Hanson Research was employed in the 
drug release experiment. The Franz Diffusion Cell System which employs six vertical, 
water jacketed Franz diffusion cells with helix spring stirrer which ensure the 
homogeneity of the sample throughout the experiment. The six cells were connector to a 
bath circulator (PolyScience, USA) that was used to maintain constant temperature 
throughout the experiment. The syringe pumps were used to withdraw the sample and 
replace it with fresh receiving medium. The last component of the system is the sample 
collector with six nozzles which delivers the sample from the Franz diffusion cells to 
the programmed position and loads it into the sample vials. 
 
 
Figure 2.6: Schematic diagram of Automated Franz Diffusion Cell System employed 
in this experiment.  
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The in vitro drug releases of the four different samples were evaluated by using 
Franz diffusion cells (Figure 2.7) with 0.636 cm
2 
of effective diffusion area and 4 mL of 
diffusate chamber volume. The diffusate compartments were filled with a 10 mM PBS 
pH 7.4, stirred at 400 rpm and thermostated at 37±1°C during all the experiments. 
Regenerated cellulose membranes with a 5000 Da molecular weight cut-off were used 
in these experiments. Pre-treatment of the membranes by soaking in the receiving 
medium were performed for 1 hour before mounted to the Franz diffusion cells. The 
regenerated cellulose membranes were sandwiched between the retentate and diffusate 
chamber. Approximately 1 g of each sample (1 g L
-1
) was placed on the membrane 
surface in the retentate chamber. Each experiment was performed by using six different 
retentate chambers for 24 hours. At predetermined intervals, samples were withdrawn 
and replaced with fresh receiving medium. These samples were spectrophotometrically 
analysed in order to obtain the concentration of salicylic acid or lidocaine as describe in 
Section 2.9. The amount of salicylic acid or lidocaine in each sample was determined 
from the standard concentration curves (Figure 2.4 and 2.5). Each data point was as the 
average of six measurements.  
 
   
Figure 2.7: Photograph of Franz Diffusion Cell. 
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CHAPTER 3 
 
RESULTS AND DISCUSSIONS 
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3.1 Particle size Analysis 
3.1.1 Effect of Homogenization Time on Mean Particle Size of SONs 
One of the objectives in this study is to prepare a stable SON dispersion with 
desired particle size (less than 500 nm). The size and physical stability of SON depends 
on the preparation parameters (time of homogenization, shear rate and sonication time), 
compositions (fatty acid compositions, concentration of surfactant and ingredients) and 
the storage temperature. A series of experiments were carried out to achieve this 
objective.  
Formation of emulsion is a non-spontaneous process and usually required 
energy input and sufficient time to disperse one liquid to another liquid phase. In this 
experiment, the effect of homogenization time on particle size was investigated. All 
SONs were prepared using the same parameters (homogenized at 15000 rpm then 
sonicated for 60 s) with varies the homogenization time from 150 s to 600 s. It was 
observed that the mean particle size of SONs greatly reduced about 21% with increased 
homogenization time from 150 s to 300 s at the same homogenization rate (Table 3.1).  
Meanwhile, the SON which homogenized for 300 s was lower polydispersity 
index than the SON which only homogenized for 150s. This is because emulsion 
droplets experienced the shear forces which overcome its interfacial force and caused 
the breakup of emulsion droplets during homogenization process. By applying the same 
shear force, sufficient homogenization time is required for the deformation and 
disruption of larger emulsion droplets into smaller ones (McClements, 1998). However, 
the mean particle size of SON only reduced about 4% with increased the 
homogenization time from 300 s to 600 s (Table 3.1). This result showed that 
homogenization for 300 s is enough time for emulsion to achieve the desired size. 
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Table 3.1: Effect of homogenization time on mean particle size and polydispersity 
index of SONs at 25°C. 
Homogenization Time (s) Mean Particle Size (nm) Polydispersity Index 
150 280 ± 4 0.34 ± 0.02 
300 221 ± 2 0.16 ± 0.02 
600 212 ± 3 0.14 ± 0.02 
 
3.1.2 Effect of Homogenization Speed on Mean Particle Size of SONs 
 
When both oil and water are mixed, two layers of liquids will eventually be 
obtained. Usually mechanical agitation is applied to mix oil and water in order to form 
emulsion.  
By maintaining other variables constant, further investigation on the particle size 
of SONs was carried out by changing the homogenization speed. There is about 14% 
reduction in mean particle size of SON that homogenized at 10000 rpm as compare to 
5000 rpm (Table 3.2). The average particle size of SON is further reduced to about 15% 
when the homogenization speed was increased up to 15000 rpm. However, it is only 
slightly reduced in mean particle size (about 6%) when homogenization speed reached 
20000 rpm.  
A more monodisperse SON dispersion was obtained with increasing 
homogenization rate from 5000 rpm up to 15000 rpm, further increased in 
homogenization rpm speed does not significantly reduced the polydispersity of 
nanoparticles. This is because droplets experience a shearing force which causing it 
rotate, circulate and become elongated during homogenization (McClements, 1998). At 
higher homogenization rate, a greater external force was exerted on to the emulsion, 
overcomes the interfacial force and consequently caused the elongated droplets broken 
up into a number of smaller droplets (Tadros, 2006). However, homogenization speed 
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was further increased up to 20000 rpm only slightly reduced the mean particle size 
about 10 nm which indicate the 15000 rpm is sufficient and used here forth. 
Table 3.2: Effect of homogenization speed on mean particle size and polydispersity 
index of SONs at 25°C. 
Homogenization Speed (rpm) Mean Particle Size (nm) Polydispersity Index 
5000 287 ± 4 0.24 ± 0.01 
10000 247 ± 3 0.23 ± 0.02 
15000 211 ± 2 0.16 ± 0.02 
20000 199 ± 3 0.12 ± 0.02 
 
3.1.3 Effect of Sonication Time on Mean Particle Size of SONs 
 
Ultrasonication process generally contributes to a mechanism of cavitation 
which the ultrasound waves resulting a mechanical depressions and compressions and 
generating cavitation and subsequently provides sufficient energy to increase the surface 
area of the emulsion hence formation of nanoemulsion (Jafari et al., 2006).  
The effect of sonication time (0 s, 30 s, 60 s and 120 s) on particle size of SON 
was investigated. A significantly reduction in mean particle size from 324 nm to 241 nm 
(about 26%) was observed (Table 3.3) when sonication applied to the pre-homogenized 
emulsion for 30 s. Smaller particles (200 nm) with lower polydispersity was obtained by 
further increasing the time of sonication up to 120 s. This may be due to sufficient time 
is need for the repetition of cavitational activities to generate smaller droplets of 
emulsion.  
Although applying sonication during preparation of SON could reduce the 
particle size, however prolong high energy input may release the titanium oxide from 
the microtip of ultrasound processor. Therefore, the maximum time for sonication 
process was limited to 120 s to avoid contamination on sample. 
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Table 3.3: Effect of sonication time on mean particle size and polydispersity index 
of SONs at 25°C. 
Sonication Time (s) Mean Particle Size (nm) Polydispersity Index 
0 324 ± 5 0.23 ± 0.02 
30 241 ± 5 0.17 ± 0.03 
60 211 ± 2 0.16 ± 0.02 
120 200 ± 3 0.12 ± 0.02 
 
3.1.4 Effect of Lipid Content on Mean Particle Size of SONs 
 
 Lipid content is one of the important parameter in the preparation of SON. 
Optimum lipid content need to be determine because higher lipid content could 
incorporate higher amount of active ingredient and the same time SON particles need to 
maintain in certain size range. The effect of lipid content in SON dispersion on average 
size of particles was investigated. For this investigation, the ratio of lipid to surfactant 
was kept constant at 4:1 and the weight of deionised water still kept at 5 g. The total 
amount of lipid content were increased from 1.25 wt%, 2.5 wt%, 5.0 wt%,  10 wt% and 
15 wt% in the formulation of SON dispersions.  
The average particle size of SONs increased linearly with increasing the lipid 
content. The mean particle size of SON dispersion increased about 60% by increasing 
the lipid content from 1.25 wt% to 15 wt% (Figure 3.1). At the same time, its 
polydispersity index also increased from about 0.1 to 0.3 with increasing the lipid 
content in the formulations. This may be due to the increased in the overall viscosity 
with an increase in the lipid content, subsequently decrease the effectiveness of 
homogenization and hence larger particles and broader particle size distributions were 
obtained (Mehnert & Mäder, 2012).  
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In this study, unloaded SON with mean particle size less than 250 nm is 
preferable because assuming of active ingredients will further enlarge the mean particle 
size of SON. Therefore, SON with 2.5 wt% lipid content, which gives an average 
particle size around 230 nm, was chosen throughout these experiments. 
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Figure 3.1: Plot of mean particle size (■) and polydispersity index (○) of SONs as 
function of lipid content at 25°C. 
 
 
3.1.5 Effect of Oleic Acid Composition on Mean Particle Size of SONs 
 
SLNs are lipid nanoparticles that composed of single or mixed solid lipids. Its 
inherence crystalline structure has known to give several advantages such as low 
loading capacity and expulsion of drugs and/or active ingredients during storage. To 
overcome these limitations, liquid oils were incorporated into lipid nanoparticles to 
effectively improve the loading efficiency of drugs and/or active compounds. However, 
the physicochemical properties of lipid nanoparticles will be difference caused by the 
incorporation of oil. In this study, oleic acid was introduced into the stearic acid matrix 
during the preparation of SON.  
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A series of SON dispersions were prepared by mixing different amount of oleic 
acid from 0 wt% to 50 wt%. It was observed that the mean particle size of SON 
depended on the amount of oleic acid in the mixture. The average particle size of 
unloaded SONs increased from 194 nm to 255 nm with increasing oleic acid amount up 
to 30 wt%, while it decreased about 13% when the oleic acid composition achieved up 
to 50 wt% (Table 3.4). These observations indicated that the excipients’ mean particle 
sizes directly affected by the amount of oleic acid in the mixture. This may be due to the 
participation of oleic acid in the formation of nanoparticles (Woo et al., 2014). However, 
the decrease in size of the particles with higher amount of oleic acid (>40 wt%) may be 
due to the incompatible mixing between stearic acid and oleic acid. 
 
Table 3.4: Mean particle size and polydispersity index of freshly prepared SONs 
with different oleic acid compositions at 25°C. 
Oleic Acid Content (wt%) Mean Particle Size (nm) Polydispersity Index 
0 194 ± 2 0.19 ± 0.01 
10 221 ± 4 0.21 ± 0.02 
20 246 ± 3 0.31 ± 0.03 
30 255 ± 3 0.37 ± 0.02 
40 229 ± 4 0.37 ± 0.01 
50 223 ± 4 0.36 ± 0.02 
 
3.1.6 Effect of Surfactant Chain Length on the Size of SON Particles 
Besides the physical nature of fatty acid in the mixture, the overall cohesive 
energy in between different mixture of composition is also expected to influence SON 
properties. Different in hydrocarbon chain length of surfactant directly affected the 
hydrophilic-lipophilic balance (HLB) and CMC values which closely associated to the 
lowering interfacial free energy and formation of emulsion droplets (Franzetti et al., 
2010).  
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A series of Tween surfactants with different hydrocarbon chain length were used 
in preparation of SONs. Tween 20, 40 and 60 were Tween type surfactants with 12, 16 
and 18 hydrocarbon chain length, respectively. The SONs stabilized by the Tween 60 
having the smallest particle size, whereas larger particles obtained with the used of 
shortest hydrocarbon chain of surfactants. From the data obtained (Figure 3.2), it is 
clearly showed that the average particle size of SON is inversely proportional to the 
hydrocarbon chain length of surfactants. The mean particle size of SONs reduced about 
40 nm with increasing the hydrocarbon chain length of Tween surfactants.   
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Figure 3.2: Plot of mean particle size (■) and polydispersity index (○) of SONs as 
function of surfactant chain length at 25°C. 
 
 HLB described the hydrophilic or lipophilic property of a surfactant based on its 
polar or non-polar moieties of the surfactant molecule. HLB value of Tween 20, 40 and 
60 is 16.7, 15.6 and 14.9, respectively (Umbreit & Strominger, 1973). Surfactant with a 
high HLB value usually form o/w emulsion and vice versa. Tween 60 has lower HLB 
value than Tween 20 and 40 indicates that it is more lipophilic which is energetically 
unfavourable in water and more likely to self-assemble into aggregates at lower 
concentration in order to minimize the hydrophobic effect. 
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Figure 3.3: Plot of surface tension as a function of ln[surfactants] of Tween 20 (□), 
Tween 40 (○) and Tween 60 (   ) at 25°C. 
 
Figure 3.3 shows that the size of SONs was associated to the CMC of surfactants. 
It was found that the CMC decreased with increasing hydrocarbon chain (Figure 3.3). 
The CMC values that obtained from this experiment were about 13 µM, 7 µM and 6 µM 
for Tween 20, Tween 40 and Tween 60, respectively. The surfactant with longer 
hydrocarbon tail has higher hydrophobic interaction between the surfactant monomers 
and able to form micelle at lower concentration. Therefore, it is able to form smaller 
emulsion droplets as compared to other Tween type surfactants with shorter 
hydrocarbon chain for the same surfactant concentration. In this case, Tween 60 was the 
best candidate among the Tween type surfactants for the preparation of SON since it 
could form the smallest particles. 
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3.1.7 Effect of Surfactant Concentration on the Size of SON Particles 
 
 The present of surfactant plays an important role in the formulation of SON to 
assist in the emulsification process and helps stabilization of lipid nanoparticles by 
absorbing onto the surface of particle and thereby sterically stabilizing the particle from 
aggregation.  
It has been shown in the previous section that Tween 60 nonionic surfactant was 
used because it has shown to produce smaller particles among the surfactants studied. A 
series of different amount of Tween 60 were used to investigate the effect of surfactant 
concentration on the particle size of SONs. It was observed that the particle size of SON 
with 2%
 w
/v of surfactant was reduced to about 60% smaller as compared to the SON 
with 0.25%
 w
/v of surfactant (Figure 3.4).  
On the other hand, SON dispersion was observed to be less turbid at higher 
concentration. The appearance of SONs changed from whitish to bluish colour with 
increasing the amount of surfactant (Figure 3.5). This phenomena indicated that the 
changes in larger size to smaller size of SON particles.  
It was reported that higher concentration of surfactant solution is more 
effectively to lower the interfacial free energy between oil and water (Riangjanapatee & 
Okonogi, 2012). Considering the data obtained from this experiment, it could be 
assumed that the small particle size of the SON obtained from the higher amount of 
Tween 60 was as consequent of decreasing interfacial free energy between the two 
immiscible lipid and aqueous phases during the emulsion forming process. 
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Figure 3.4: Plot of mean particle size (■) and polydispersity index (○) of SONs as 
function of surfactant concentration (%
w
/v) at 25°C. 
 
 
Figure 3.5: SON dispersions stabilized by (a) 0.25%
 w
/v, (b) 0.50%
 w
/v, (c) 1.00%
 w
/v, 
(d) 1.50%
 w
/v and (e) 2.00%
 w
/v of Tween 60. 
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3.1.8 Effect of Active Compounds in the Composition on the Particle Size of 
SONs 
 
 As a carrier system, SONs are able to carry active ingredients or drugs by 
encapsulating them into its matrix. In this study, two active ingredients namely salicylic 
acid and lidocaine were chosen for the encapsulation into lipid matrix and their effect on 
mean particle size of SONs with 30 wt% oleic acid was investigated.  
A dramatically increased about 27% in the mean particle sizes of SON with 30 
wt% oleic acid loaded with 5 mg of salicylic acid was observed as compared to its 
unloaded SONs (Table 3.5). The size of SONs was further increased 378 nm when 
amount of salicylic acid added up to 30 mg. The substantially increased in mean particle 
size was indicated that the salicylic acid participation in the formation of SON 
nanoparticles (Woo et al., 2014). Similar results for incorporation of other active 
ingredients or drugs into lipid nanoparticles have also been reported (Chattopadhyay et 
al., 2007; Das et al., 2012).  
At the same time, an interesting funding for SONs with 30 wt% oleic acid 
containing lidocaine was observed. Besides a similar increasing trend in size of SONs 
with lidocaine was observed, it is also found that smaller particles were obtained as 
compared to SONs with salicylic acid (Table 3.5). This is may be due to the lidocaine is 
more compatible with the SON matrix as compared to salicylic acid.  
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Table 3.5: Mean particle size and polydispersity index of freshly prepared salicylic 
acid or lidocaine loaded SON with 30 wt% oleic acid at 25°C. 
Amount of Active 
Ingredients (mg) 
Salicylic Acid loaded SONs Lidocaine loaded SONs 
Mean Particle 
Size (nm) 
Polydispersity 
Index 
Mean Particle 
Size (nm) 
Polydispersity 
Index 
0 255 ± 2 0.37 ± 0.02 255 ± 2 0.37 ± 0.02 
5 324 ± 2 0.36 ± 0.02 270 ± 4 0.33 ± 0.04 
10 332 ± 3 0.37 ± 0.02 284 ± 5 0.35 ± 0.02 
20 351 ± 4 0.36 ± 0.02 297 ± 3 0.37 ± 0.02 
30 378 ± 3 0.30 ± 0.04 321 ± 3 0.23 ± 0.02 
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3.2 Accelerated Stability Studies of SON 
3.2.1 Effect of Surfactant Concentration 
Nanoparticle stability was the major concern as the suspension stability exerted a 
great impact on the suspension ability to be practically functional and the capability to 
resist destabilization throughout the lifetime of the product. The destabilisation of lipid 
nanoparticles could be visually determined by observing the physically changes such as 
present of large particles, sedimentation or colour change from clear to turbid. Besides 
that, it is also could quantitatively determine by measuring the change in particle size 
and surface charge for certain period. 
A series of SON with different amount of surfactant were prepared and stored at 
45°C for accelerated stability study. Any change in particle size can be monitored from 
particle size measurement carried out at each day (Figure 3.6). SONs with Tween 60 
concentration up to 0.5%
 w
/v in formulation only marginally increased about 15 nm in 
particle size. However, SONs with 1.0%
w
/v of Tween 60 showed gradually increased in 
particle size about 20% and significantly increased about 70% and 220% for 1.5%
w
/v 
and 2.0%
w
/v, respectively. This result suggested that the Tween 60 concentration should 
not exceed 1.0%
w
/v in the SON formulation.  
The zeta potential values of SONs were gradually reduced as the concentrations 
of Tween 60 was increased (Table 3.6). This is may be due to the adsorption of Tween 
60 onto the surface of lipid nanoparticles and hindered the carboxyl functional group of 
fatty acid which contributing the negative surface change and subsequently reduced the 
zeta potential of lipid nanoparticle.  
Although smaller particles could be obtained by increasing the surfactant 
concentration, it may not suitable to be used in preparation of SONs due to other factors 
such as size, polydispersity and surface charged that directly influence its stability also 
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need to take into consideration. Therefore, the concentration of Tween 60 in SON 
formulation in this case was kept constant at 0.5%
w
/v for the further experiments.  
 
 
Figure 3.6: Accelerated stability of SON dispersions with different surfactant 
concentration in formulation at 45°C for 1 day (■) and 4 days (□) of storage. 
 
Table 3.6: Zeta potential value of freshly prepared SONs with different surfactant 
concentrations at 25°C. 
Surfactant Concentration (%w/v) Zeta Potential (mV) 
0.25 -53.0 ± 0.5 
0.50 -48.2 ± 0.3 
1.00 -46.2 ± 0.4 
1.50 -45.9 ± 0.5 
2.00 -44.1 ± 0.9 
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3.2.2 Effect of Storage Temperature  
 
Colloidal suspensions in general are thermodynamically unstable system and 
destabilization is easily stimulated by their surrounding temperature and pressure. 
Destabilization may occur due to the improper storage condition of SON particles 
especially at high temperature. Therefore, it is important to investigate the effect of 
temperature on stability of SON dispersions. In this study, SON dispersions were stored 
at 5°C, room temperature (about 28°C) and 45°C, respectively and their mean particle 
sizes were determined by using dynamic light scattering technique at certain time 
intervals for 28 days. SONs also observed under TEM microscopy to visualise the 
change in the morphology. 
 The change in particle size of SON dispersions when stored at different 
temperatures is shown in Figure 3.7. There is almost no significant change in particle 
size for SON stored at 5°C for 28 days. A gradual increase in particle size from 240 nm 
to 350 nm for SON stored at room temperature. This is in agreement the TEM 
micrographs that showed present of larger particles. Moreover, sedimentation of 
particles was also observed for SON dispersion that stored at room temperature as 
shown in Figure 3.8. However, SON dispersion which stored at 45°C showed 
dramatically increased in mean particle size up to about one micron during 28 days of 
storage (Figure 3.7). Large and irregular spherical shape particles were also observed in 
TEM micrographs. A denser sedimentation of particles was also observed for sample 
stored at 45°C (Figure 3.8). These observations indicated that the stability of SON 
suspension was greatly influent by the storage temperature. This could be explained that 
at elevated temperature, frequency of collision among particles increases and lower 
electrostatic repulsion between incoming particles lead to particle aggregation. Hence, 
this speeds up flocculation process that eventually leads to larger aggregates. Besides 
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the aggregation, the nanoparticles may be partially melted and fused to become large 
irregular shape particles. 
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Figure 3.7:  Plot of mean particle size of SON dispersions as function of storage time 
at 5°C (■), room temperature (about 28°C) () and 45°C () and the TEM micrographs 
showed the changes in shape of nanoparticles, scale bar is 1 µm. 
 
 
Figure 3.8:  Photograph of SONs stored at different temperatures (a) 5°C (left), (b) 
room temperature (middle) and (c) 45°C (right) after 28 days showing denser 
sedimentation. 
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3.3 Effect of Oleic Acid Composition on the Morphologies of SONs 
 
Oleic acid is in liquid form at room temperature. The present of oleic acid 
composition may disrupt the internal crystalline structure of stearic acid in SON 
particles. To visualize the effect of oleic acid composition on morphologies of 
nanoparticles, freshly prepared SONs were observed using TEM microscopy. Figure 3.9 
showed the TEM micrographs of SONs with different oleic acid compositions. The 
morphology of SON without oleic acid appeared to be more monodisperse spherical 
shape and relatively small particle size.  
When about 30 wt% of oleic acid in the compositions of SON, the particles 
appeared to be larger and starting to be elongate as shown in Figure 3.9 (b). When the 
oleic acid composition increased to 50 wt%, most of the particles appeared as elongated 
particles as shown in Figure 3.9 (c). The TEM micrographs revealed that the higher 
oleic acid composition led to the formation of elongated particles with larger particle 
size.  
The surface area to volume ratio of elongated particles is assumed to be bigger 
as compared to spherical shape SON. The elongated particles are not preferable because 
its low surface area to volume ratio may limit the contact area of particles to be 
absorbed onto the skin surface. However, certain amount of oleic acid is needed to 
improve the encapsulation efficiency of SON. Therefore, it is not recommended to 
incorporate high amount of oleic acid into SON. 
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(a) 
 
(b) 
 
(c) 
Figure 3.9: TEM micrographs of SONs. (a) SON without oleic acid, (b) SON with 
30 wt% oleic acid composition, (c) SON with 50 wt% oleic acid composition, scale bar 
is 500 nm. 
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3.4 Differential Scanning Calorimetry (DSC) 
 
DSC has been extensively employed in the lipid nanoparticles research to assess 
the thermal parameters such as melting point, melting enthalpy and degree of 
crystallinity. One of the features of lipid nanoparticles is they occur as rigid 
nanoparticles at both room temperature and body temperature and this unique property 
gives controlled release of payloads. To improve encapsulation efficiency of active 
ingredients, lipid nanoparticles were produce by mixing of solid lipid and oily lipid. 
However, addition of oily lipid into solid lipid matrix may change the overall melting 
parameters of the lipid nanoparticles. In this study, the effect of oleic acid concentration 
in the composition on melting behaviour of SON particles was investigated. 
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Figure 3.10: Endothermic thermogram of stearic acid at the heating rate of 5°C min-1. 
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Figure 3.10 showed the endothermic thermogram of stearic acid and the melting 
parameters such as melting point, onset temperature and melting enthalpy of stearic acid 
were analysed by using TA Universal Analysis software. The peak of the endothermic 
thermogram indicates the melting point of stearic acid and onset temperatures is 
obtained from the intersection of the tangent of the endothermic peak with the 
extrapolated baseline. The shaded area of the endothermic thermogram is proportional 
to the melting enthalpy of stearic acid which is 226 J g
-1
. 
All the endothermic thermograms of both salicylic acid and lidocaine loaded 
SONs showed one endothermic peak and the melting point shifts towards lower 
temperature accompanied by increasing in the width of the melting peak (Figure 3.111 
and 3.12). The melting point of SON with salicylic acid gradually decreased about 12°C 
from 0 wt% to 50 wt% oleic acid content (Table 3.7). Similar result was also obtained 
for SON with lidocaine. The melting point of SON with lidocaine also decreased about 
17°C as oleic acid composition increased from 0 wt% to 50 wt% (Table 3.8).  
The degree of crystallinity of SONs was determined by calculating the ratio of 
SON melting enthalpy to stearic acid melting enthalpy as shown in the equation (4) at 
Section 2.7, Chapter 2. Taking the enthalpy of pure stearic acid at 226 J g
-1
 as 100%, the 
theoretical percentage of crystallinity of SONs with 10, 20, 30, 40 and 50 wt% oleic 
acid could then be obtained (Mühlen & Mehnert, 1998). The degree of crystallinity of 
SONs with salicylic acid was dramatically reduced about 60% with increasing oleic acid 
ratio from 0 wt% to 50 wt% (Table 3.7). Expectedly, the degree of crystallinity of SONs 
with lidocaine also was significantly decreased about 50% with increasing oleic acid 
ratio from 0 wt% to 50 wt% (Table 3.8). These could conclude that the present of oleic 
acid somehow perturb the stearic acid crystal matrix and increase the amorphous 
proportion in particles, leading to reduction in the degree of crystallinity of SONs.  
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Table 3.7: Onset temperatures (Tonset), melting points, melting enthalpies (∆H) and 
degree of crystallinity of SONs with and without salicylic acid. 
Oleic Acid 
Content 
(wt%) 
Salicylic Acid loaded SONs 
Tonset (°C) Melting Point (°C) ∆H (J/g) 
Degree of Crystallinity 
(%) 
0 65.9 68.8 188 83 
10 63.1 67.2 158 70 
20 59.9 65.5 119 53 
30 55.8 62.9 98 43 
40 49.0 59.2 78 35 
50 44.2 56.5 60 27 
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Figure 3.11: Endothermic thermograms of salicylic acid loaded SONs with 0 – 50 wt% 
oleic acid composition at the heating rate of 5°C min-1. 
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Table 3.8 Onset temperatures (Tonset), melting points, melting enthalpies (∆H) and 
degree of crystallinity of SONs with and without lidocaine. 
Oleic Acid 
Content 
(wt%) 
Lidocaine loaded SONs 
Tonset (°C) Melting Point (°C) ∆H (J/g) 
Degree of Crystallinity 
(%) 
0 65.3 69.0 178 79 
10 62.1 67.1 160 71 
20 59.2 65.2 136 61 
30 55.4 62.8 115 51 
40 50.5 60.2 98 44 
50 48.0 58.3 73 32 
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Figure 3.12: Endothermic thermograms of lidocaine loaded SONs with 0 – 50 wt% 
oleic acid composition at the heating rate of 5°C min-1. 
  
64 
  
3.5 Encapsulation Efficiency of SONs 
 
 For a carrier system, it is important to encapsulate the active ingredients as much 
as possible. In lipid nanoparticles research, one of the strategies to improve 
encapsulation efficiency of carrier is to produce the lipid nanoparticles with the mixture 
of liquid oil and solid lipid. In this study, SONs were prepared by mixture of stearic 
acid and oleic acid as mentioned in Chapter 2. The encapsulation efficiency of salicylic 
acid loaded SONs increased from 49% to 69% with increasing the oleic acid 
composition from 0 wt% to 40 wt%, respectively, but slightly decreased to 63% for 50 
wt% oleic acid content as shown in Figure 3.13. A substantially increased in the 
encapsulation efficiency of lidocaine loaded SONs from 50% to 70% with increasing 
the oleic acid composition up to 30 wt% and subsequently remains around ±70% as 
oleic acid composition increased up to 50 wt%.  
Encapsulation efficiency has always been correlated with the degree of 
crystallinity of lipid nanoparticles (Almeida et al., 2012). It has been shown in previous 
section that the addition of oleic acid into SONs composition increases the amorphous 
state in the solid lipid matrix and decreases the overall particle crystallinity, thereby 
improves the encapsulation efficiency. This has been explained the reason of increased 
in encapsulation efficient of both active ingredients as amount of oleic acid in the 
mixture increased. Jenning et al. also reported that incorporation of liquid oil into lipid 
nanoparticles perturbed the crystalline matrix and results enough space to accommodate 
retinol molecules, thus increased the drug encapsulation capacity (Jenning et al., 2000). 
This is further supported by Ribeiro et al. that encapsulation efficiency of lipid 
nanoparticles was directly proportional to the oleic acid concentration in the lipid phase 
(Ribeiro et al., 2012).  
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However, the encapsulation efficiency of SONs containing large amount of oleic 
acid (50 wt%) slightly decreased which may be due to exclusion of oleic acid during 
crystallization of SONs that unable to incorporate higher amount of salicylic acid (Kim 
et al., 2010; Lin et al., 2007). On the other hand, the encapsulation efficiency of 
lidocaine loaded SONs remained around 70% owing the fact that lidocaine has higher 
preferential in lipid phase as compared to salicylic acid. Log P value is the indicator that 
showed the solubility of a particular compound in octane and water. Positive log P 
value indicated that a particular compound is preferable to dissolve in organic phase and 
vice versa. Lidocaine has higher log P value (2.44) as compared to salicylic acid which 
the log P value is around 2.26.  
SONs with 30 wt%, 40 wt% and 50 wt% oleic acid composition demonstrated 
high loading efficiency of salicylic acid or lidocaine with similar sizes but SON with 30 
wt% oleic acid content was considered as an optimized formulation because SONs with 
higher oleic acid concentration present as elongated solid particles that have lower 
melting behaviour and excess oleic acid content may easily oxidized especially when 
there is unexpected temperature fluctuation during storage and transportation. 
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Figure 3.13: Plot of encapsulation efficiency of salicylic acid (■) and lidocaine (○) 
loaded SONs as function of oleic acid composition at 25°C. 
  
67 
  
3.6 In Vitro Release Evaluation 
 
SON with 30 wt% oleic acid content was selected owing to its optimum 
formulation property based on the results obtained from our particle size, morphology, 
thermal behaviour and encapsulation efficiency analysis. It was then further 
incorporated into a cream formulation for the in vitro release investigation.  
Eight different samples as described in Section 2.11 were evaluated using Franz 
Diffusion Cell system and the cumulative amount of salicylic acid or lidocaine release 
from all samples were plotted against time as shown in Figure 3.14 and Figure 3.15, 
respectively. Sample A to D are the samples containing salicylic acid whereas Sample E 
to H are samples containing lidocaine. For samples containing salicylic acid, Samples A 
showed a rapid released within 8 hours whereas the Sample B, C and D demonstrated a 
biphasic release pattern whereby a rapid release of salicylic acid was observed in the 
first 8 hours followed by slower release at almost a constant rate (Figure 3.14). The 
initial fast release rates of Sample B, C and D could be due to the presence of free 
salicylic acid molecules in the aqueous phase which diffuse rapidly through the 
membrane. After the completion of the first phase of free salicylic acid within the first 8 
hours, it is followed by the second phase which is much slower release rate that could 
be due to the retention of salicylic acid in the SON particle dispersion and/or in the 
emulsion. Sample C and D have slower release behaviour as compared to the samples 
without SON. The presence of controlled release behaviour for samples containing SON 
(Sample C and D) revealed that the salicylic acid molecules were successfully 
incorporated in the solid matrix of SON and slowly release from the particles. Similar 
results were also obtained for samples containing lidocaine. Sample E has substantially 
released within 6 hours whereas Sample F, G and H showed a faster rate of release 
followed by slower rate of release (Figure 3.15). 
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Figure 3.14: In vitro release study of salicylic acid solution (   ), salicylic acid cream 
(   ), salicylic acid loaded SON with 30 wt% oleic acid composition (   ) and salicylic 
acid loaded SON with 30 wt% oleic acid composition in cream (   ) over a period of 24 
hours at 37°C. 
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Figure 3.15: In vitro release study of lidocaine solution (   ), lidocaine cream (   ), 
lidocaine loaded SON with 30 wt% oleic acid composition (   ) and lidocaine loaded 
SON with 30 wt% oleic acid composition in cream (    ) over a period of 24 hours at 
37°C. 
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In order to understand their release kinetic, the in vitro releases of the eight 
different samples were curve fitted to zero order, first order and Higuchi model. We 
have chosen the Higuchi model because it could describe diffusion of drug from 
homogenous and granular matrix system (Vivek et al.,  2007). The release profiles of 
the eight samples showed the best fit into Higuchi model (R
2
 > 0.95 - 0.99) (Table 3.9). 
The linear fits of all samples indicated that the release of salicylic acid or lidocaine from 
the samples was diffusion controlled process (Vivek et al., 2007).  
 
Table 3.9: Different kinetic model evaluations of payloads (salicylic acid or 
lidocaine) release for eight different samples at 37C. 
Sample 
Zero Order First Order Higuchi Model 
Slope R
2
 Slope R
2
 Slope R
2
 
A 10.5 0.93 0.20 0.77 38.4 0.99 
B 2.4 0.89 0.07 0.69 14.4 0.98 
C 1.8 0.92 0.08 0.70 10.5 0.99 
D 0.9 0.81 0.02 0.62 5.2 0.95 
E 15.8 0.98 0.34 0.83 50.8 0.99 
F 4.0 0.96 0.11 0.67 22.9 0.99 
G 2.2 0.93 0.11 0.65 12.6 0.99 
H 1.4 0.97 0.12 0.65 8.0 0.99 
 
The slopes which obtained from the plotting of Higuchi model (Table 3.9) 
represent the release rate of payload (Shah & Hanson, 2003). The release rates of 
samples containing salicylic acid were followed the sequence of Sample A > B > C > D 
and the release rates of samples containing lidocaine were Sample E > F > G > H. The 
release rate of Sample A and E (solution form) were reduced after formulated into 
cream (Sample B and F) revealed this retentional effect by the emulsion. For cream that 
containing SON with salicylic acid or lidocaine (Sample D and H), the release rates 
were further decreased to about 3 times as compared to cream formulations (Sample B 
and F) and it is indicating that the SON prepared in this study has slow release property. 
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This slow release property of SON could be due to the release of active ingredients from 
the solid matrix of SON particle which involved two pathways as illustrated in Figure 
3.16. In the retentate chamber, the payloads slowly released (  ) from the particles to 
the aqueous phase and then diffused through the membrane at the faster rate (  ) 
(Figure 3.16). The reason of slow release of payloads at the first pathway may be due to 
the hydrophobic solid matrix of SON retards the release of salicylic acid or lidocaine to 
the aqueous phase, thus results in slower release rate.  
 
  
Figure 3.16: Schematic diagram for in vitro release mechanism of SON with active 
ingredients in Franz Diffusion Cell. 
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CHAPTER 4 
 
CONCLUSION 
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4.1 Conclusion 
A series of SONs were successfully prepared by using melt-emulsification 
combined with ultrasonication method and a series of experiments were carried out to 
investigate the influence of device parameters such as speed and time of 
homogenization and period of sonication in order to obtain smaller particles with 
narrow size distributions. The optimized preparation parameters of SONs are 
homogenizing at 15000 rpm for 300 s and followed by 120 s of sonication.  
It was also found that the SON compositions such as lipid content, surfactant 
concentration and amount of active ingredients directly influenced the particle size of 
nanoparticles. The size of nanoparticles was increased linearly with increased in the 
lipid content. The particle size also varied with the oleic acid composition in the mixture. 
At the same time, TEM images showed that higher amount of oleic acid concentration 
in the mixture led to formation of elongated SON particles. On the other hands, small 
size of nanoparticles could be obtained by increasing the amount of surfactant in SON. 
The participation of active ingredients in formation of SON particles also resulted larger 
particles. The prepared nanoparticles with both salicylic acid and lidocaine possessed a 
mean particle size of about 250 nm to 330 nm. The stability of SONs was also evaluated 
by monitoring the change of particle size of SON which stored at different temperatures 
(5°C, room temperature and 45°C). The results showed that the particle size of SON 
maintained stable at 5°C for 4 weeks.  
Encapsulation efficiency for salicylic acid and lidocaine increased from 50% to 
70% with increasing amount of oleic acid into SON composition. This could be 
explained by the results of DSC analysis which was showed that the decreased in degree 
of crystallinity of SONs with increasing oleic acid composition in the mixture. Different 
amount of oleic acid mixed gave different degree of perturbation to the crystalline 
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matrix of SONs hence result in lower degrees of crystallinity, thereby improve their 
encapsulation efficiencies. SON with 30 wt% oleic acid content was considered as an 
optimized formulation because it demonstrated high loading efficiency for both salicylic 
acid and lidocaine with similar sizes. 
In vitro release of salicylic acid or lidocaine in samples such as solution, cream, 
SON dispersion and SON into the cream was evaluated by using Franz Diffusion Cell 
technique. The in vitro release study showed that SON dispersion performed a gradual 
release for 24 hours as compared to its solution form and cream, denoting the 
incorporation of salicylic acid or lidocaine in solid matrix of SON and prolonged the in 
vitro release. Both salicylic acid and lidocaine in cream formulation which containing 
SONs has about 3 times slower release rate as compared to its solution form, suggesting 
the potential use of SON as carrier to improve therapeutic efficacy in cosmetic and 
pharmaceutical products. 
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